Psychedelics Today, Author at PsyNews.com

Home Authors Posts by admin

2168 POSTS 0 COMMENTS

https://psynews.com

PT481 – Kanna: The History, Science, and Potential of an Emerging...

Pα+ Psychedelic Bulletin #154: Public & Industry Respond to DEA’s Renewed...

Ensuring the Affordable Becomes Accessible – Lessons from Ketamine’s Antidepressant Development...

European Union Grants €6.5M for Multi-Site Psilocybin Study in Palliative Patients

PT480 – Psychedelics and Consent: Power Dynamics, Boundaries, and the Concept...

The Psychedelic News Feed: Dec 11 2023 – Jan 7, 2024

Psychedelics M&A and Partnerships in 2023

PT479 – Psilocybin in the Midwest and the Need for Potency...

Psychedelic Funding & Public Markets in 2023

Pα+: Knowledge Gaps in Psychedelic Medicalisation, According to ECNP and Regulators

1...313233...217 Page 32 of 217

EDITOR PICKS

Pα+ Psychedelic Bulletin #185: Joe Rogan on Ibogaine; Wisconsin Medicaid to...

Billionaire Investor Antonio Gracias Plots $100M Lykos Takeover with Doblin’s Backing

Can Legalization Serve the Greater Good? The Ethical Challenges of Psychedelic...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

admin